BR0108448A - Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor - Google Patents

Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor

Info

Publication number
BR0108448A
BR0108448A BR0108448-8A BR0108448A BR0108448A BR 0108448 A BR0108448 A BR 0108448A BR 0108448 A BR0108448 A BR 0108448A BR 0108448 A BR0108448 A BR 0108448A
Authority
BR
Brazil
Prior art keywords
substituted
unsubstituted
amino
antitumor activity
alkenyl
Prior art date
Application number
BR0108448-8A
Other languages
English (en)
Inventor
Tatsuo Higa
Junichi Tanaka
Dolores Garcia Gravalos
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0003629A external-priority patent/GB0003629D0/en
Priority claimed from GB0021774A external-priority patent/GB0021774D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0108448A publication Critical patent/BR0108448A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"DERIVADOS DE TETRAIDROFURIL óXI- E AMINO-SUBSTITUìDOS COM ATIVIDADE ANTITUMOR". Os compostos de fórmula (I), em que os grupos substituintes definidos por R~ 1~, R~ 2~, R~ 3~ e R~ 4~ são, cada um, independentemente selecionados de H, C(=O)R, P(=O)R'R", S(=O)R'R", C~ 1~-C~ 18~ alquila substituída ou não substituída, C~ 2~-C~ 18~ alquenila substituída ou não-substituída, C~ 2~-C~ 18~ alquinila substituída ou não-substituída, arila substituída ou não-substituída; em que cada um dos grupos R', R" é independentemente selecionado a partir do grupo consistindo em H, OH, NO~ 2~, NH~ 2~, SH, CN, halogênio, =O, C(=O)H, C(=O)CH~ 3~, CO~ 2~H, CO~ 2~CH~ 3~, C~ 1~-C~ 18~ alquila substituída ou não-substituída, C~ 2~C~ 18~ alquenila substituída ou não-substituída, C~ 2~-C~ 18~ alquinila substituída ou não-substituída, arila substituída ou não-substituída; em que R~ 1~, R~ 2~, R~ 3~ poderiam formar parte de um anel heterocíclico; R~ 2~ pode ser independentemente um sal interno; em que X~ 1~, X~ 2~ e X~ 3~ na fórmula (I) são independentemente colocados em qualquer posição particular da cadeia e independentemente selecionados de H, OH, OR', SH, SR', SOR', SO~ 2~R', NO~ 2~, NH~ 2~, NHR', N(R')~ 2~, NHC(O)R', CN, halogênio, =O, C(=O)H, C(=O)CH~ 3~, CO~ 2~H, CO~ 2~CH~ 3~, C~ 1~-C~ 18~ alquila substituída ou não-substituída, C~ 2~-C~ 18~ alquenila substituída ou não-substituída, C~ 2~-C~ 18~ alquinila substituída ou não substituída, arila substituída ou não-substituída, heteroaromático substituído ou não-substituído; em que os grupos substituintes definidos por R' são, cada um, independentemente selecionados do grupo consistindo em H, OH, OR', SH, SR', SOR', SO~ 2~R', NO~ 2~, NH~ 2~, NHR', N(R')~ 2~, NHC(O)R', CN, halogênio, =O, C(=O)H, C(=O)CH~ 3~, CO~ 2~H, CO~ 2~CH~ 3~, C~ 1~-C~ 18~ alquila substituída ou não-substituída, C~ 2~-C~ 18~ alquenila substituída ou não-substituída, C~ 2~-C~ 18~ alquinila substituída ou não-substituída, arila substituída ou não-substituída, heteroaromático substituído ou não-substituído; em que x pode ser entre 6 e 20; e em que a linha pontilhada é uma ou diversas ligações duplas colocadas em qualquer posição particular da cadeia lateral; são úteis como compostos antitumor e incluem o composto IK-8-73-4 de estrutura (a), o qual foi isolado de uma esponja Pachastrissa sp.
BR0108448-8A 2000-02-16 2001-02-16 Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor BR0108448A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0003629A GB0003629D0 (en) 2000-02-16 2000-02-16 Antitumour agent
GB0021774A GB0021774D0 (en) 2000-09-05 2000-09-05 Anti-tumour compound
PCT/GB2001/000655 WO2001060810A1 (en) 2000-02-16 2001-02-16 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity

Publications (1)

Publication Number Publication Date
BR0108448A true BR0108448A (pt) 2003-04-01

Family

ID=26243662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108448-8A BR0108448A (pt) 2000-02-16 2001-02-16 Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor

Country Status (17)

Country Link
US (1) US6864283B2 (pt)
EP (1) EP1255746B1 (pt)
JP (1) JP2003523338A (pt)
KR (1) KR20020092958A (pt)
CN (1) CN1318409C (pt)
AT (1) ATE316524T1 (pt)
AU (2) AU3387301A (pt)
BR (1) BR0108448A (pt)
CA (1) CA2400612C (pt)
CZ (1) CZ20022791A3 (pt)
DE (1) DE60116855T2 (pt)
ES (1) ES2256199T3 (pt)
IL (1) IL151241A (pt)
MX (1) MXPA02007995A (pt)
PL (1) PL357193A1 (pt)
RU (1) RU2002124591A (pt)
WO (1) WO2001060810A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255746B1 (en) 2000-02-16 2006-01-25 Pharma Mar, S.A. Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity
CN102229585A (zh) * 2011-04-26 2011-11-02 中国人民解放军第二军医大学 具有抗肿瘤活性的γ-丁内酯聚酮类化合物
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007507C (en) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine and n-methyl-sphingosine as inhibitor of cell growth
US5583160A (en) * 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US6107520A (en) * 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
EP1255746B1 (en) 2000-02-16 2006-01-25 Pharma Mar, S.A. Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity

Also Published As

Publication number Publication date
MXPA02007995A (es) 2003-05-23
CA2400612A1 (en) 2001-08-23
ES2256199T3 (es) 2006-07-16
ATE316524T1 (de) 2006-02-15
IL151241A (en) 2006-10-31
EP1255746B1 (en) 2006-01-25
CA2400612C (en) 2010-05-11
CN1318409C (zh) 2007-05-30
KR20020092958A (ko) 2002-12-12
EP1255746A1 (en) 2002-11-13
AU3387301A (en) 2001-08-27
DE60116855D1 (de) 2006-04-13
WO2001060810B1 (en) 2001-11-29
CZ20022791A3 (cs) 2003-02-12
DE60116855T2 (de) 2006-09-14
RU2002124591A (ru) 2004-01-10
PL357193A1 (en) 2004-07-26
CN1423642A (zh) 2003-06-11
AU2001233873B2 (en) 2006-03-02
US6864283B2 (en) 2005-03-08
WO2001060810A1 (en) 2001-08-23
US20030092738A1 (en) 2003-05-15
JP2003523338A (ja) 2003-08-05

Similar Documents

Publication Publication Date Title
ATE253051T1 (de) Chinolinderivate und chinazolinderivate
FR18C1006I2 (fr) Derives de quinoline ayant un groupe azolyle et derives de quinazoline
ATE180468T1 (de) Anthranilsäure derivate
MXPA04001240A (es) Analogos antitumorales.
ATE275134T1 (de) 4-oxo-1,4-dihydro-3-chinolincarboxamide als antivirale mittel
ATE303063T1 (de) Synthetische analoge des ecteinascidin-743
ATE156836T1 (de) 11,21-bisphenyl-19-nor-pregnan derivate
ATE513821T1 (de) Thiadiazolin-derivate zur behandlung von krebs
ATE204272T1 (de) Neue pyridon carbonsäure-derivate
BR0108448A (pt) Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
HK1060354A1 (en) Variolin derivatives and their use as antitumor agents
ATE311182T1 (de) Benzopyranderivate zur behandlung von perihperer gefässerkrankung
TH17157A (th) อนุพันธ์ไพริมิดีนอะไซโคลนิวคลีโอไซด์

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009